Core Insights - The company has reported an upward trend in the market price of experimental monkeys and has taken measures to ensure a stable supply to meet operational needs [3][4] - The growth of the company's overseas business is driven by a deepened global layout, improved business systems, and enhanced comprehensive service capabilities [4][6] - The company is focusing on building innovative technology platforms related to human cell models, AI predictions, and organoids, while also strengthening its preclinical capabilities in biopharmaceuticals [5][6] Group 1: Supply and Pricing - The market price of experimental monkeys has been increasing recently, prompting the company to diversify procurement channels and deepen cooperation with suppliers to ensure a stable supply [3][4] Group 2: Overseas Business Growth - The company's overseas business growth is attributed to a comprehensive global strategy, including the establishment of a 2,000 square meter R&D office in Boston, which has already begun generating revenue [4][6] - The company is enhancing its laboratory capabilities and business team configurations in key overseas regions, improving communication between overseas business development and domestic research teams [4][6] Group 3: Technology Platform Development - The company is advancing its innovative technology platforms, focusing on areas such as CGT, nucleic acid drugs, PROTAC, and AI, with ongoing projects in ADC preclinical research [5][6] - The company has completed numerous ADC preclinical studies and received 30 approvals, indicating a strong capability in this area [5][6] Group 4: Capacity and Talent Management - The company operates R&D laboratories in multiple locations, including Zhangjiang, Chuansha, Nanhui, and Boston, with ongoing expansion projects to enhance drug discovery and research capabilities [6][7] - The company plans to dynamically recruit talent based on business needs, focusing on technical and management personnel, while also implementing internal training and incentive mechanisms [6][7] Group 5: Project Execution Cycles - The company has three service models with varying execution cycles: product customization (1-3 months for chemical/biological services, 1-10 months for pharmacodynamics), design and development (approximately 6 months to 2.5 years), and joint efforts (typically 6 months to 1 year) [8]

Core Viewpoint - Haichuang Pharmaceutical (688302.SH) has received approval from the National Medical Products Administration of China for clinical trials of HP518 tablets in combination with anti-tumor drugs for the treatment of advanced prostate cancer, marking a significant step in the development of innovative cancer therapies [1] Group 1: Clinical Trial Approval - The company has been granted a Clinical Trial Approval Notice for HP518 tablets to conduct Phase Ib/II clinical trials for advanced prostate cancer [1] - HP518 has also received approval for clinical trials in China, Australia, and the United States, with no similar products currently approved for market [1] Group 2: Drug Mechanism and Advantages - HP518 is composed of a target protein ligand, an E3 ligase ligand, and a linker, which induces the ubiquitination of the androgen receptor (AR) and relies on proteasomal degradation to deeply inhibit the AR signaling pathway, achieving anti-tumor effects [1] - As a new oral PROTAC drug, HP518 exhibits typical advantages such as catalytic activity, high selectivity, and good safety profile [1] Group 3: Efficacy and Potential - Preclinical studies have shown that HP518 has high degradation activity against both resistant AR mutants and wild-type AR proteins, demonstrating excellent anti-cancer activity against AR-dependent prostate cancer cells [1] - The drug is expected to address resistance issues caused by mutations in prostate cancer treatment, providing new therapeutic options for this patient population [1]

Core Viewpoint - Haichuang Pharmaceutical (688302.SH) has received approval from the National Medical Products Administration of China for clinical trials of HP518 tablets in combination with anti-tumor drugs for the treatment of advanced prostate cancer, marking a significant step in the development of innovative cancer therapies [1] Company Summary - HP518 tablets have been approved for clinical trials in China, Australia, and the United States for advanced prostate cancer, with no similar products currently approved for market [1] - The drug is composed of a target protein ligand, an E3 ligase ligand, and a linker, which induces the ubiquitination of the androgen receptor (AR) and relies on proteasomal degradation to deeply inhibit the AR signaling pathway, achieving anti-tumor effects [1] - As a novel PROTAC oral drug, HP518 has shown high degradation activity against both resistant AR mutants and wild-type AR proteins in preclinical studies, demonstrating excellent anti-cancer activity against AR-dependent prostate cancer cells [1] Industry Summary - The approval of HP518 tablets represents a potential breakthrough in addressing treatment resistance caused by mutations in prostate cancer, providing new therapeutic options for patients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 承董事會命 北京昭衍新藥研究中心股份有限公司 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 附件為本公司於上海證券交易所網站刊登之 北京昭衍新藥研究中心股份有限公司 (1) 關於召開2025年半年度業績說明會的公告 (2) 2025年半年度報告 (3) 2025年半年度報告摘要 馮宇霞 董事長 中 國 北 京，2025年8月26日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 ...